Developer docs
API playgroundTry for free, no card

Search company profiles

Cyrus Therapeutics

Full company profile

uuid0002rl4

Namestring
Cyrus Therapeutics
Legal namestring
Cyrus Therapeutics, Inc.
Websiteurl
cyrustx.com
Company typeenum
Private
Founded yearint
2019
Descriptiontext

Cyrus Therapeutics is a South Korean clinical-stage biotechnology company founded in 2019 by Byong-Moon Kim (former Head of R&D at CJ Healthcare) and a team of industry veterans from Novartis, Pfizer, Roche, Sanofi, Dana-Farber/Harvard, and major Korean pharma. The company pursues a "drugging the undruggable targets" thesis, building an integrated drug discovery platform centered on small molecule inhibitors and Targeted Protein Degradation (TPD) modalities including PROTACs, Molecular Glue Degraders (MGDs), and Degrader-Antibody Conjugates (DACs). Its proprietary CyPath/CyFinder engine handles target identification and candidate optimization using structure-based design, CADD, and AI-augmented molecular modeling. The pipeline spans eight R&D programs, with CYRS1542 (oral GSPT1 molecular glue degrader for neuroendocrine cancers) leading as the first clinical-stage asset after FDA and MFDS IND approvals in 2025, alongside an SOS1 inhibitor co-developed with Kanaph Therapeutics, a CDK7 inhibitor, and EGFR degraders with Bridge Biotherapeutics. The company is exploring expansion beyond oncology into immune-inflammatory diseases via a September 2025 collaboration with Dong-A ST.

Cyrus operates a B2B licensing and co-development business model rather than direct commercialization. Revenue mechanics consist of upfront payments, development and approval milestones, and royalties from out-licensing drug candidates to large pharmaceutical partners. Notable transactions include a ₩208 billion SOS1 inhibitor deal with Yuhan Corporation (₩60B upfront, March 2024), a ₩24.8 billion HDNO-1765 oral GLP-1 deal with Hyundai Pharm (2020), and ₩70 billion of equity from Yuhan in November 2024. Co-development partnerships with Kanaph Therapeutics, Bridge Biotherapeutics, Mokgam Life Science Institute, and Dong-A ST share costs and risks across the pipeline. The company is funded through Series A (₩10B, 2020), Series B (₩29B, 2022), and a Series C round in progress, with global business development conducted at AACR and BIO USA conferences. Primary customers are global and Korean pharmaceutical companies seeking differentiated oncology and TPD pipeline assets.

Short descriptiontext

Cyrus Therapeutics is a South Korean clinical-stage biotech (founded 2019) developing small molecule inhibitors and targeted protein degraders (PROTACs, molecular glue degraders, DACs) for oncology and metabolic diseases, generating revenue through B2B out-licensing and co-development deals with global and Korean pharmaceutical partners.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersSongpadong, South Korea
HQ citystring
Songpadong
HQ countrystring
South Korea
HQ regionstring
Asia
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
targeted protein degradation, small molecule drug discovery, molecular glue degraders, oncology drug development, degrader antibody conjugates
Industry3 codes
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Oncology Therapeutics
No data
GTM motion2 records

Each record includes

Type, Description, Source

Revenue model3 records
1Technology Licensing / Out-licensing
TypeLicensing Royalties
Description

Cyrus generates revenue through out-licensing its drug candidates to large pharmaceutical companies. Notable deal: SOS1 inhibitor licensed to Yuhan for up to ₩208 billion (₩60B upfront + milestone payments). CYRS1542 is being developed for global licensing. The company also licensed HDNO-1765 (oral GLP-1) to Hyundai Pharm for ₩248B (₩8B upfront + ₩240B milestones).

cyrustx.com
2Co-development Partnerships
TypeLicensing Royalties
Description

Revenue generated through co-development agreements with partners where costs and outcomes are shared. Partnerships include SOS1 inhibitor co-developed with Kanaph Therapeutics (licensed to Yuhan), EGFR PROTAC with Bridge Biotherapeutics, ARM platform with Mokgam Life Science Institute (GC Biopharma), and immunology/inflammation drug with Dong-A ST.

cyrustx.com
3Equity Investment
TypeLicensing Royalties
Description

The company has raised capital through equity financing. Series A (2020): ₩100B from Parasus Investment, Kolon Investment, Timefolio Asset Management. Series B (2022): ₩290B from existing investors plus Mirae Asset Capital, Mirae Asset Venture Investment, AT-Num Investment, and GC Biopharma. Series C is in progress. Yuhan invested ₩70B for equity stake in 2024.

cyrustx.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Core offering1 text field

Cyrus Therapeutics discovers and develops small molecule drugs and targeted protein degraders (PROTACs, molecular glue degraders, and degrader-antibody conjugates) to drug previously undruggable targets in cancer and metabolic diseases. The company operates proprietary discovery platforms including a CRBN E3 ligase-based molecular glue degrader library, a degrader-antibody conjugate (DAC) platform, and the CyPath/CyFinder drug discovery engine, supporting a pipeline of approximately eight research programs across oncology and metabolic indications.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • CYRS1542 demonstrated complete tumor regression (CR) in SCLC (NCI-H526 CDX) and NSCLC (NCI-H1155 CDX) models at high doses, with no tumor relapse after discontinuation of treatment.
+3 more records
Product overview1 text field

Cyrus Therapeutics is a biotechnology company discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs. The company operates a multi-modality drug discovery platform focused on 'drugging the undruggable targets' using small molecule inhibitors, targeted protein degraders (TPDs) including PROTACs and molecular glue degraders, and degrader-antibody conjugates (DACs). The core product pipeline includes CYRS1542 (oral GSPT1 molecular glue degrader for neuroendocrine cancers), SOS1 inhibitors (co-developed with Kanaph, licensed to Yuhan), CDK7 inhibitors, and EGFR degraders (with Bridge Biotherapeutics). The company targets oncogenic pathways including RAS/MAP kinases, DNA damage response, cell cycle, and transcriptional regulation with emphasis on synthetic lethal targets.

Product and service4 records
1CYRS1542
CategoryTargeted Protein Degradation / Oncology
Description

Oral GSPT1 molecular glue degrader that induces tumor regression by degrading GSPT1, a translation termination factor essential for cancer cell survival. Developed for neuroendocrine solid cancers including small cell lung cancer (SCLC) and castration-resistant prostate cancer. Licensed to pharmaceutical partners for global development and commercialization.

2SOS1 Inhibitor (CK-1001/YH44529)
CategorySmall Molecule Inhibitor / Oncology
Description

Small molecule inhibitor targeting SOS1 protein that regulates KRAS activation. Effective against KRAS and EGFR mutant cancers including lung, colon, and pancreatic cancers. Licensed to Yuhan Corporation for global exclusive rights.

3CDK7 Inhibitor (C-16661)
CategorySmall Molecule Inhibitor / Oncology
Description

Novel cyclin-dependent kinase 7 inhibitor for various solid tumors and hematologic malignancies. Shows efficacy in breast cancer and addresses resistance to CDK4/6 inhibitors. Developed for licensing or co-development with pharmaceutical partners.

4EGFR Degraders
CategoryTargeted Protein Degradation / Oncology
Description

Targeted protein degraders (PROTACs) for EGFR mutations in non-small cell lung cancer, including single and compound EGFR mutations. Co-developed with Bridge Biotherapeutics to overcome EGFR TKI resistance. Targets NSCLC patients with EGFR mutations, including those resistant to existing EGFR tyrosine kinase inhibitors.

Scale indicator4 records

Each record includes

Type, Value, Description, Source

Partnership10 partners
1Dong-A ST (동아에스티)
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-09-16
Description

Cyrus and Dong-A ST signed a joint research agreement for the development of molecular glue degrader drugs for immunology and inflammation disease treatment. Cyrus contributes its proprietary molecular glue degrader library and screening system for target candidate identification; Dong-A ST provides preclinical and clinical development capabilities. This expands Cyrus's modality beyond oncology into immune-inflammatory diseases.

cyrustx.com
Strategic tierFlagshipTypeStrategic or Co-development PartnerAnnounced on2024-03-07
Description

Yuhan licensed the global exclusive rights to the SOS1 inhibitor (CK-1001, YH44529) co-developed by Cyrus and Kanaph Therapeutics for ₩208 billion (₩60B upfront + milestone payments). The SOS1 inhibitor addresses KRAS/EGFR-mutant cancers including NSCLC, colorectal cancer, and pancreatic cancer. Yuhan also invested ₩70 billion for equity stake in Cyrus in late 2024.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cyrus and Kanaph Therapeutics co-developed the SOS1 inhibitor program, combining Cyrus's medicinal chemistry capabilities with Kanaph's drug fusion technology. The co-developed asset was licensed to Yuhan. The partnership leverages complementary drug development platforms for next-generation cancer therapeutics.

4Bridge Biotherapeutics
Strategic tierCoreTypeStrategic or Co-development Partner
Description

Cyrus and Bridge Biotherapeutics co-develop EGFR protein degraders (PROTACs) for NSCLC patients with EGFR mutations, including those resistant to existing EGFR TKIs. The collaboration leverages Cyrus's TPD platform and Bridge's EGFR inhibitor development expertise. Also supported by KDDF funding and collaboration with Yonsei Cancer Center.

cyrustx.com
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a research collaboration partner on Cyrus's website for drug discovery acceleration. Specific collaboration details are not extensively detailed in available sources.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner on Cyrus's website. GC Biopharma participated in Cyrus's Series B investment round. Collaboration scope includes broader drug discovery partnerships.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Cyrus signed a joint research agreement with Mokgam Life Science Institute (under GC Biopharma) to develop anticancer drugs using the ARM (Antibody Recruiting Molecule) platform. Cyrus is responsible for lead compound design, synthesis, and SAR research; Mokgam handles target discovery, in vitro/in vivo efficacy studies, and lead selection.

Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a research collaboration partner on Cyrus's website, specifically involved in EGFR PROTAC research with patient-derived cancer cell studies.

9College of Pharmacy, Seoul National University (SNU)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Listed as a collaboration partner on Cyrus's website for drug discovery acceleration.

cyrustx.com
10Seoul National University - Professor Kang Geon-wook (강건욱)
Strategic tierMinorTypeStrategic or Co-development Partner
Description

Academic collaboration for CYRS1542 drug mechanism and biomarker research, including in vivo NSCLC model studies where complete response was maintained after treatment discontinuation.

cyrustx.com
Recent move6 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight6 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Clinical-stage biotech developing molecular glue degraders with a direct overlap to Cyrus's GSPT1 MGD program; both companies pursue CRBN-based glue degraders against oncology targets.

TypeDirect peer
Description

Clinical-stage TPD biotech developing heterobifunctional degraders and molecular glues against oncology and immunology targets; directly comparable modality and stage.

TypeDirect peer
Description

Develops targeted protein degraders using a DNA-encoded library platform against oncology targets; comparable modality and partnership-driven business model.

TypeDirect peer
Description

TPD-focused biotech developing small-molecule degraders across oncology indications, using a comparable degrader chemistry and discovery platform approach.

TypeEmerging player
Description

Oncology-focused biotech using chromatin biology platform; overlaps with Cyrus's oncology focus and translational science capabilities though with a different core modality.

TypeDirect peer
Description

Pioneer of PROTAC-based targeted protein degradation with clinical-stage assets in oncology; operates the same broad TPD modality that Cyrus leverages for its degrader pipeline.

TypeBroad incumbent
Description

Global pharma with protein degradation programs and home to Cyrus CSO Wooseok Han's prior tenure; pursues TPD and degrader-antibody conjugate strategies overlapping Cyrus's platform.

8Bristol Myers Squibb
TypeBroad incumbent
Description

Large pharma that developed CC-90009, a GSPT1 molecular glue degrader explicitly cited as a competitor to Cyrus's CYRS1542; pursues broad oncology pipeline including TPD.

9Bridge Biotherapeutics
TypeRegional player
Description

Korean biotech co-developing EGFR PROTACs with Cyrus; comparable Korean clinical-stage oncology biotech with similar out-licensing and co-development orientation.

TypeDirect peer
Description

Korean biotech co-developing the SOS1 inhibitor with Cyrus that was licensed to Yuhan; directly comparable Korean oncology biotech with complementary fusion technology.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
Yes
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds2 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors7 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Cyrus Therapeutics

Oncology Therapeuticscyrustx.com

Cyrus Therapeutics is a South Korean clinical-stage biotech (founded 2019) developing small molecule inhibitors and targeted protein degraders (PROTACs, molecular glue degraders, DACs) for oncology and metabolic diseases, generating revenue through B2B out-licensing and co-development deals with global and Korean pharmaceutical partners.

What Cyrus Therapeutics does

Cyrus Therapeutics is a South Korean clinical-stage biotechnology company founded in 2019 by Byong-Moon Kim (former Head of R&D at CJ Healthcare) and a team of industry veterans from Novartis, Pfizer, Roche, Sanofi, Dana-Farber/Harvard, and major Korean pharma. The company pursues a "drugging the undruggable targets" thesis, building an integrated drug discovery platform centered on small molecule inhibitors and Targeted Protein Degradation (TPD) modalities including PROTACs, Molecular Glue Degraders (MGDs), and Degrader-Antibody Conjugates (DACs). Its proprietary CyPath/CyFinder engine handles target identification and candidate optimization using structure-based design, CADD, and AI-augmented molecular modeling. The pipeline spans eight R&D programs, with CYRS1542 (oral GSPT1 molecular glue degrader for neuroendocrine cancers) leading as the first clinical-stage asset after FDA and MFDS IND approvals in 2025, alongside an SOS1 inhibitor co-developed with Kanaph Therapeutics, a CDK7 inhibitor, and EGFR degraders with Bridge Biotherapeutics. The company is exploring expansion beyond oncology into immune-inflammatory diseases via a September 2025 collaboration with Dong-A ST.

Cyrus operates a B2B licensing and co-development business model rather than direct commercialization. Revenue mechanics consist of upfront payments, development and approval milestones, and royalties from out-licensing drug candidates to large pharmaceutical partners. Notable transactions include a ₩208 billion SOS1 inhibitor deal with Yuhan Corporation (₩60B upfront, March 2024), a ₩24.8 billion HDNO-1765 oral GLP-1 deal with Hyundai Pharm (2020), and ₩70 billion of equity from Yuhan in November 2024. Co-development partnerships with Kanaph Therapeutics, Bridge Biotherapeutics, Mokgam Life Science Institute, and Dong-A ST share costs and risks across the pipeline. The company is funded through Series A (₩10B, 2020), Series B (₩29B, 2022), and a Series C round in progress, with global business development conducted at AACR and BIO USA conferences. Primary customers are global and Korean pharmaceutical companies seeking differentiated oncology and TPD pipeline assets.

Cyrus Therapeutics firmographics

Firmographics
Name
Cyrus Therapeutics
Legal name
Cyrus Therapeutics, Inc.
Website
https://cyrustx.com
Company type
Private
Founded year
2019
Operating status
Operating
Headcount range
11–50 employees
Short description
Cyrus Therapeutics is a South Korean clinical-stage biotech (founded 2019) developing small molecule inhibitors and targeted protein degraders (PROTACs, molecular glue degraders, DACs) for oncology and metabolic diseases, generating revenue through B2B out-licensing and co-development deals with global and Korean pharmaceutical partners.
Ownership category
akta.pro rank

Cyrus Therapeutics industry classification

Industry
Product category
Oncology Therapeutics
NAICS
Research and Development in Biotechnology (except Nanobiotechnology) (541714)
SIC
Pharmaceutical Preparations (2834)
akta.pro industry
PRIMARYHLAIALAA
Drug Discovery (Target ID/Validation & Hit Discovery)
Healthcare & Life Sciences/Pharmaceuticals/Pharmaceutical Research and Development
SECONDARYHLAAAIAI
Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)
SECONDARYHLAAAIAC
Protein Engineering & Directed Evolution Platforms (enzyme/therapeutic protein optimization)
Healthcare & Life Sciences/Biotechnology & Biologics/Biologic Drug Discovery Platforms (screening, antibody engineering, synthetic biology)

Keywords

  • Targeted protein degradation
  • Small molecule drug discovery
  • Molecular glue degraders
  • Oncology drug development
  • Degrader antibody conjugates

Where Cyrus Therapeutics is headquartered

Location

Headquarters

HQ city
Songpadong
HQ country
South Korea
HQ region
Asia

Offices1 record

Markets served

Cyrus Therapeutics business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Technology or R&D, Operations, Marketing or Sales, Infrastructure

Revenue model

  1. Technology Licensing / Out-licensing: Cyrus generates revenue through out-licensing its drug candidates to large pharmaceutical companies. Notable deal: SOS1 inhibitor licensed to Yuhan for up to ₩208 billion (₩60B upfront + milestone payments). CYRS1542 is being developed for global licensing. The company also licensed HDNO-1765 (oral GLP-1) to Hyundai Pharm for ₩248B (₩8B upfront + ₩240B milestones).
  2. Co-development Partnerships: Revenue generated through co-development agreements with partners where costs and outcomes are shared. Partnerships include SOS1 inhibitor co-developed with Kanaph Therapeutics (licensed to Yuhan), EGFR PROTAC with Bridge Biotherapeutics, ARM platform with Mokgam Life Science Institute (GC Biopharma), and immunology/inflammation drug with Dong-A ST.
  3. Equity Investment: The company has raised capital through equity financing. Series A (2020): ₩100B from Parasus Investment, Kolon Investment, Timefolio Asset Management. Series B (2022): ₩290B from existing investors plus Mirae Asset Capital, Mirae Asset Venture Investment, AT-Num Investment, and GC Biopharma. Series C is in progress. Yuhan invested ₩70B for equity stake in 2024.

Go-to-market motion2 records

Distribution channels2 records

Marketing channels5 records

Cyrus Therapeutics product offering

Product offering

Core offering

Cyrus Therapeutics discovers and develops small molecule drugs and targeted protein degraders (PROTACs, molecular glue degraders, and degrader-antibody conjugates) to drug previously undruggable targets in cancer and metabolic diseases. The company operates proprietary discovery platforms including a CRBN E3 ligase-based molecular glue degrader library, a degrader-antibody conjugate (DAC) platform, and the CyPath/CyFinder drug discovery engine, supporting a pipeline of approximately eight research programs across oncology and metabolic indications.

Product overview

Cyrus Therapeutics is a biotechnology company discovering and developing innovative medicines to conquer chronic or life-threatening diseases with high unmet needs. The company operates a multi-modality drug discovery platform focused on 'drugging the undruggable targets' using small molecule inhibitors, targeted protein degraders (TPDs) including PROTACs and molecular glue degraders, and degrader-antibody conjugates (DACs). The core product pipeline includes CYRS1542 (oral GSPT1 molecular glue degrader for neuroendocrine cancers), SOS1 inhibitors (co-developed with Kanaph, licensed to Yuhan), CDK7 inhibitors, and EGFR degraders (with Bridge Biotherapeutics). The company targets oncogenic pathways including RAS/MAP kinases, DNA damage response, cell cycle, and transcriptional regulation with emphasis on synthetic lethal targets.

Differentiator

Problem solved

Functional benefit

Products and services

  • CYRS1542 Oral GSPT1 molecular glue degrader that induces tumor regression by degrading GSPT1, a translation termination factor essential for cancer cell survival. Developed for neuroendocrine solid cancers including small cell lung cancer (SCLC) and castration-resistant prostate cancer. Licensed to pharmaceutical partners for global development and commercialization.
  • SOS1 Inhibitor (CK-1001/YH44529) Small molecule inhibitor targeting SOS1 protein that regulates KRAS activation. Effective against KRAS and EGFR mutant cancers including lung, colon, and pancreatic cancers. Licensed to Yuhan Corporation for global exclusive rights.
  • CDK7 Inhibitor (C-16661) Novel cyclin-dependent kinase 7 inhibitor for various solid tumors and hematologic malignancies. Shows efficacy in breast cancer and addresses resistance to CDK4/6 inhibitors. Developed for licensing or co-development with pharmaceutical partners.
  • EGFR Degraders Targeted protein degraders (PROTACs) for EGFR mutations in non-small cell lung cancer, including single and compound EGFR mutations. Co-developed with Bridge Biotherapeutics to overcome EGFR TKI resistance. Targets NSCLC patients with EGFR mutations, including those resistant to existing EGFR tyrosine kinase inhibitors.

Quantifiable outcome

  • CYRS1542 demonstrated complete tumor regression (CR) in SCLC (NCI-H526 CDX) and NSCLC (NCI-H1155 CDX) models at high doses, with no tumor relapse after discontinuation of treatment.
  • +3 more outcomes

Companies that use Cyrus Therapeutics

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles1 record

Cyrus Therapeutics technology and API

Technology

Technology focussed Yes

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

Cyrus Therapeutics partnerships and signals

Strategic signal

Partnerships

Ten partnerships are on record, tiered core, flagship and minor.

  • Dong-A ST (동아에스티)coreStrategic or Co-development Partner · 16 September 2025Cyrus and Dong-A ST signed a joint research agreement for the development of molecular glue degrader drugs for immunology and inflammation disease treatment. Cyrus contributes its proprietary molecular glue degrader library and screening system for target candidate identification; Dong-A ST provides preclinical and clinical development capabilities. This expands Cyrus's modality beyond oncology into immune-inflammatory diseases.
  • Yuhan CorporationflagshipStrategic or Co-development Partner · 7 March 2024Yuhan licensed the global exclusive rights to the SOS1 inhibitor (CK-1001, YH44529) co-developed by Cyrus and Kanaph Therapeutics for ₩208 billion (₩60B upfront + milestone payments). The SOS1 inhibitor addresses KRAS/EGFR-mutant cancers including NSCLC, colorectal cancer, and pancreatic cancer. Yuhan also invested ₩70 billion for equity stake in Cyrus in late 2024.
  • Kanaph TherapeuticscoreStrategic or Co-development PartnerCyrus and Kanaph Therapeutics co-developed the SOS1 inhibitor program, combining Cyrus's medicinal chemistry capabilities with Kanaph's drug fusion technology. The co-developed asset was licensed to Yuhan. The partnership leverages complementary drug development platforms for next-generation cancer therapeutics.
  • Bridge BiotherapeuticscoreStrategic or Co-development PartnerCyrus and Bridge Biotherapeutics co-develop EGFR protein degraders (PROTACs) for NSCLC patients with EGFR mutations, including those resistant to existing EGFR TKIs. The collaboration leverages Cyrus's TPD platform and Bridge's EGFR inhibitor development expertise. Also supported by KDDF funding and collaboration with Yonsei Cancer Center.
  • St. Jude Children's Research HospitalminorStrategic or Co-development PartnerListed as a research collaboration partner on Cyrus's website for drug discovery acceleration. Specific collaboration details are not extensively detailed in available sources.
  • GC BiopharmaminorStrategic or Co-development PartnerListed as a collaboration partner on Cyrus's website. GC Biopharma participated in Cyrus's Series B investment round. Collaboration scope includes broader drug discovery partnerships.
  • Mokgam Life Science Institute (목암생명과학연구소)minorStrategic or Co-development PartnerCyrus signed a joint research agreement with Mokgam Life Science Institute (under GC Biopharma) to develop anticancer drugs using the ARM (Antibody Recruiting Molecule) platform. Cyrus is responsible for lead compound design, synthesis, and SAR research; Mokgam handles target discovery, in vitro/in vivo efficacy studies, and lead selection.
  • Yonsei Cancer CenterminorStrategic or Co-development PartnerListed as a research collaboration partner on Cyrus's website, specifically involved in EGFR PROTAC research with patient-derived cancer cell studies.
  • College of Pharmacy, Seoul National University (SNU)minorStrategic or Co-development PartnerListed as a collaboration partner on Cyrus's website for drug discovery acceleration.
  • Seoul National University - Professor Kang Geon-wook (강건욱)minorStrategic or Co-development PartnerAcademic collaboration for CYRS1542 drug mechanism and biomarker research, including in vivo NSCLC model studies where complete response was maintained after treatment discontinuation.

Scale indicators4 records

Recent moves6 records

Expansion highlights6 records

Cyrus Therapeutics competitors and assessment

Company assessment

Direct peers

  • Monte Rosa Therapeutics: Clinical-stage biotech developing molecular glue degraders with a direct overlap to Cyrus's GSPT1 MGD program; both companies pursue CRBN-based glue degraders against oncology targets.
  • Kymera Therapeutics: Clinical-stage TPD biotech developing heterobifunctional degraders and molecular glues against oncology and immunology targets; directly comparable modality and stage.
  • Nurix Therapeutics: Develops targeted protein degraders using a DNA-encoded library platform against oncology targets; comparable modality and partnership-driven business model.
  • C4 Therapeutics: TPD-focused biotech developing small-molecule degraders across oncology indications, using a comparable degrader chemistry and discovery platform approach.
  • Arvinas: Pioneer of PROTAC-based targeted protein degradation with clinical-stage assets in oncology; operates the same broad TPD modality that Cyrus leverages for its degrader pipeline.
  • Kanaph Therapeutics: Korean biotech co-developing the SOS1 inhibitor with Cyrus that was licensed to Yuhan; directly comparable Korean oncology biotech with complementary fusion technology.

Emerging players

  • Foghorn Therapeutics: Oncology-focused biotech using chromatin biology platform; overlaps with Cyrus's oncology focus and translational science capabilities though with a different core modality.

Broad incumbents

  • Novartis: Global pharma with protein degradation programs and home to Cyrus CSO Wooseok Han's prior tenure; pursues TPD and degrader-antibody conjugate strategies overlapping Cyrus's platform.
  • Bristol Myers Squibb: Large pharma that developed CC-90009, a GSPT1 molecular glue degrader explicitly cited as a competitor to Cyrus's CYRS1542; pursues broad oncology pipeline including TPD.

Regional players

  • Bridge Biotherapeutics: Korean biotech co-developing EGFR PROTACs with Cyrus; comparable Korean clinical-stage oncology biotech with similar out-licensing and co-development orientation.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks6 records

Key highlights7 records

Customer concentration

Cyrus Therapeutics financial estimates

Financial estimate

Revenue estimate

Valuation estimate

Cyrus Therapeutics leadership team

Management profile

Number of profiles

Profiles1 record

Cyrus Therapeutics funding detail

Funding detail

Funding overview

Funding rounds2 records

Investors7 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

Cyrus Therapeutics M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about Cyrus Therapeutics

What does Cyrus Therapeutics do?

Cyrus Therapeutics discovers and develops small molecule drugs and targeted protein degraders (PROTACs, molecular glue degraders, and degrader-antibody conjugates) to drug previously undruggable targets in cancer and metabolic diseases. The company operates proprietary discovery platforms including a CRBN E3 ligase-based molecular glue degrader library, a degrader-antibody conjugate (DAC) platform, and the CyPath/CyFinder drug discovery engine, supporting a pipeline of approximately eight research programs across oncology and metabolic indications.

Is Cyrus Therapeutics a public or private company?

Cyrus Therapeutics is a private company. It is classified as venture growth investor backed and is currently operating.

When was Cyrus Therapeutics founded?

Cyrus Therapeutics was founded in 2019. It employs 11 to 50 people.

Where is Cyrus Therapeutics based?

Cyrus Therapeutics is headquartered in Songpadong, South Korea, in the Asia region.

How does Cyrus Therapeutics make money?

Three revenue lines are on record. Technology Licensing / Out-licensing is the primary driver. The others are co-development Partnerships and equity Investment.

Who are Cyrus Therapeutics's main competitors?

Direct peers on record are Monte Rosa Therapeutics, Kymera Therapeutics, Nurix Therapeutics, C4 Therapeutics, Arvinas and Kanaph Therapeutics. Foghorn Therapeutics is listed as an emerging player. Broad incumbents are Novartis and Bristol Myers Squibb. Bridge Biotherapeutics is listed as a regional player.

Does Cyrus Therapeutics have an API?

No public API is recorded for Cyrus Therapeutics.

What industry is Cyrus Therapeutics in?

Cyrus Therapeutics's product category is Oncology Therapeutics. Its primary akta.pro industry code is HLAIALAA, Drug Discovery (Target ID/Validation & Hit Discovery), with a secondary code of HLAAAIAI, Target Identification & Validation Platforms (omics-driven, chemoproteomics, genetic validation). Its NAICS code is 541714 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals